Arovella Therapeutics Ltd
Company Profile
Business description
Arovella Therapeutics Ltd is engaged in the development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer. Its invariant Natural Killer T (iNKT) cell therapy platform is being developed as a next-generation, allogeneic off-the-shelf cell therapy platform with potential applications across blood cancers, solid tumours and selected autoimmune diseases. Its product, ALA-101, is a CD19-directed CAR-iNKT cell therapy for relapsed or refractory CD19- positive blood cancers. Arovella is expanding the platform into solid tumours through ALA-105, its CLDN18.2-targeting CAR-iNKT program for gastric and pancreatic cancers, and through incorporation of IL-12-TM armouring technology designed to enhance CARiNKT cell activity and durability.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
44
Stocks News & Analysis
stocks
Our view after Coles’ shares plunge
stocks
Cheap ASX share remains overlooked by the market
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.10 | 46.30 | -0.51% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,437.41 | 142.99 | 0.61% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,534.22 | 244.11 | 0.39% |
| NZX 50 Index | 13,698.63 | 98.37 | -0.71% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,858.80 | 49.30 | -0.55% |
| SSE Composite Index | 3,640.93 | 41.91 | 1.16% |